Proof-of-concept development of a cost-effective PACE-based assay for CYP2C19 genotyping
Article Sidebar
Main Article Content
Abstract
Background: Pharmacogenomic testing of the CYP2C19 gene is a fundamental component of precision medicine, enabling personalized dose adjustments for critical medications, including antiplatelet agents and antidepressants. However, the high cost of currently available commercial genotyping kits creates a financial burden that limits patient accessibility to these essential tests.
Objectives: This study aimed to preliminarily develop and analytically evaluate a novel PCR Allelic Competitive Extension (PACE) assay for genotyping CYP2C19*2, *3, and *17.
Materials and methods: Thirty DNA samples extracted from buffy coat were analyzed using specifically designed allele-specific primers for CYP2C19*2, *3, and *17. The genotyping results were reported as zygosity status and evaluated for concordance with the TaqManTM Drug Metabolism Genotyping Assay.
Results: The analysis identified *1/*1 (53.3%), *1/*2 (30.0%), *1/*3 (10.0%), and *2/*2 (6.7%) genotypes, while the allele frequencies were 73.3% for *1, 21.7% for *2, 5.0% for *3, and 0% for *17. The results from the PACE technique demonstrated 100% concordance with those obtained from the commercial TaqManTM assay and produced clear, well-separated data points in the allelic discrimination plot analysis.
Conclusion: The novel PACE technique provides high accuracy, equivalent to commercially available test kits, while offering a more cost-effective approach, with a reagent cost of only USD 4.34 (135 Thai baht) per sample for CYP2C19*2, *3, and *17 genotyping. It represents an alternative to CYP2C19 genotyping, supporting the advancement of personalized medicine and reducing the longterm financial burden on healthcare.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
Abdelmonem HB, Abdelaal NM, Anwer EKE, Rashwan AA, Hussein MA, Ahmed YF, et al. Decoding the role of CYP450 enzymes in metabolism and disease: A comprehensive review. Biomedicines. 2024; 12(7): 1467. doi: 10.3390/biomedicines12071467.
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021; 22(23): 12808. doi: 10.3390/ijms222312808.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17(3): 165-84. doi: 10.1007/s40291-013-0028-5.
Kittipanprayoon S, Vorasayan P, Chutinet A, Chariyavilaskul P, Suwanwela NC. The prevalence of CYP2C19 polymorphism in patients with symptomatic intracranial atherosclerosis. Cerebrovasc Dis Extra. 2025; 15(1): 68-72. doi: 10.1159/000543331.
Zhou Y, Lauschke VM. Population pharmacogenomics: An update on ethnogeographic differences and opportunities for precision public health. Hum Genet. 2022; 141(6): 1113-36. doi: 10.1007/s00439-021-02385-x.
Nieh HV, Roman YM. Major allele frequencies in CYP2C9 and CYP2C19 in Asian and European populations: A case study to disaggregate data among large racial categories. J Pers Med. 2025; 15(7): 274. doi: 10.3390/jpm15070274.
Sukprasong R, Chuwongwattana S, Koomdee N, Jantararoungtong T, Prommas S, Jinda P, et al. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. Sci Rep. 2021; 11(1): 12343. doi: 10.1038/s41598-021-90969-y.
Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for primary care: An overview. Genes (Basel). 2020; 11(11): 1337. doi: 10.3390/genes11111337.
Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front Pharmacol. 2024; 15: 1326776. doi: 10.3389/fphar.2024.1326776.
Larsen JB, Rasmussen JB. Pharmacogenetic testing revisited: 5’ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19. Pharmgenomics Pers Med. 2017; 10: 115-28. doi: 10.2147/PGPM.S131580.
Cervinski MA, Schwab MC, Lefferts JA, Lewis LD, Lebel KA, Tyropolis AM, et al. Establishment of a CYP2C19 genotyping assay for clinical use. Am J Clin Pathol. 2013; 139(2): 202-7. doi: 10.1309/AJCP9K2KDOCPCBSV.
Lopez-Ortiz C, Reddy UK, Zhang C, Natarajan P, Nimmakayala P, Benedito VA, et al. QTL and PACE analyses identify candidate genes for anthracnose resistance in tomato. Front Plant Sci. 2023; 14: 1200999. doi: 10.3389/fpls.2023.1200999.
Ali GS, Eltaher S, Li J, Freeman B, Singh S. GWAS identifies a polyembryony locus in mango: Development of KASP and PACE markers for marker-assisted breeding. Front Plant Sci. 2025; 16: 1508027. doi: 10.3389/fpls.2025.1508027.
Rudell EC, Cutti L, Turra GM, Angonese PS, Tasca VF, Dos Santos OD, et al. Variability and spatial distribution of ALS-inhibitor resistance mechanisms in Brazilian Echinochloa crus-galli. Plant Physiol Biochem. 2025; 228: 110237. doi: 10.1016/j.plaphy.2025.110237.
Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998; 17(8): 857-72. doi:10.1002/(sici)10970258(19980430)17: 8<857::aid-sim777>3.0.co;2-e.
Wang J, Yang Y, Xia B. A simplified Cohen’s Kappa for use in binary classification data annotation tasks. IEEE Access. 2019; 7: 164386-97. doi: 10.1109/ACCESS.2019.2953104.
Areesinpitak T, Kanjanawart S, Nakkam N, Tassaneeyakul W, Vannaphasaht S. Prevalence of CYP2C19, CYP3A4 and FMO3 genetic polymorphisms in healthy northeastern Thai volunteers. ScienceAsia. 2020; 46(4): 397-402. doi: 10.2306/scienceasia1513-1874.2020.050.
Nakhonsri V, John S, Panumasmontol H, Jantorn M, Chanthot P, Hanpramukkun N, et al. The diversity of CYP2C19 polymorphisms in the Thai population: Implications for precision medicine. Ther Clin Risk Manag. 2024; 20: 95-105. doi: 10.2147/TCRM.S443815.
Caudle KE, Whirl-Carrillo M, Relling MV, Hoffman JM, Donnelly RS, Haidar CE, et al. Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacetics Implementation Consortium (CPIC). Clin Pharmacol Ther. 2025; 118(6): 1512-22. doi: 10.1002/cpt.3685.
Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022; 112(5): 959-67. doi: 10.1002/cpt.2526.
Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021; 109(6): 1417-23. doi: 10.1002/cpt.2015.
